UnitedHealth Group (UNH)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-15
$375.93-1.99%
Close 2026-09-15 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-15
Research Workspace
Put UNH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — annual revenue growth of at least 1%: Q2 FY26 rev +0.0% vs 1% target.
View ThesisRevenue growth is slowing — up about 6% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskUnitedHealth's growth in the Optum segment must continue to justify its current valuation. Revenue growth has slowed, with Q2 FY26 revenue at 0.0% year over year, missing the 1% target. The stock trades at 20.6× P/E, below the peer median of 22.2×, indicating that expectations are modest compared to our view. The primary risk is the recent leadership change, which could undermine strategic direction and execution quality. Peer multiples imply a price about 5% above where it trades. This read is provisional.
Trailing returns as of 2026-09-15. UNH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 27 analysts currently covering UNH (as of Sep 2026).
Based on 16 Wall Street analysts offering 12-month price targets for UNH in the last 4 months.
Continue this research
Compare UNH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| UNH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Compare the value case
Put UNH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance growth and operational improvements in Optum businesses
Highlights growth potential in Optum through AI advancements.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $375.93
The last 12 months of price, then the range of analyst 12-month targets from today’s $375.93.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Raise 2026 EPS outlook to $19.50-$20.00 per share
Upbeat 2026 outlook supports EPS growth target.
Advances: Advance growth and operational improvements in Optum businesses
Partnership enhances growth in Optum businesses.
Threatens: Maintain disciplined cost management and improve operating margins
CFO's comments suggest potential cost management issues.
Threatens: Expand UnitedHealthcare consumer base and improve operating margins
Coverage denial may harm consumer base expansion efforts.
Advances: Expand UnitedHealthcare consumer base and improve operating margins
Strengthens competitive position in Medicare Advantage market.
Threatens: Expand UnitedHealthcare consumer base and improve operating margins
Cuts could hinder consumer base expansion and margins.
Advances: Advance growth and operational improvements in Optum businesses
Improved trends in Optum support growth objectives.
